诺和诺德宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理用于体重管理。此次上市申请是基于III期STE

智通财经
Jul 09, 2025
诺和诺德宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理用于体重管理。此次上市申请是基于III期STEP UP研究和III期STEP UP T2D研究的积极结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10